Insights & Best Practices for Pharma Professionals

Why a European list price is not a paid price, and which European baskets amplify a single price change.

Five errors that break international price comparisons, and the six countries where a comparison is defensible today.

The authority price database that exists but is closed to commercial users, and the three alternatives.

30 national price sources compared by price level, update frequency and licence status.

One clinical assessment for the EU, and every pricing decision still national. The dates, the boundaries and the data consequences.

495 confidential discounts against 92 paybacks in a 13 country analysis, and the reference pricing loop that explains why.

Fourteen countries, four different answers to the same question about the manufacturer price.

Four real country baskets, the circularity problem, and the reason confidential rebates exist at all.

The best identification model in Europe and the least transferable price concept, in one country.

Both price levels published, the method documented, and a currency question that changes rankings without any price moving.

Three price levels in one row, two to three consolidations a month, and a licence position that exists nowhere in writing.

Purchase and retail price per pack and per unit, a daily file, and a route that is nowhere documented.

Price, national code, GTIN and pack size from one openly licensed source, and four price fields that answer four different questions.

An open interface under CC BY 4.0, a monthly archive back to 2014, and a dispensing fee that has to come off first.

A legally fixed two week rhythm, a 380 euro cost recovery fee, and prices in øre that cost a factor of one hundred.

Four price levels in one row, a GTIN everywhere, and four characters in a licence name that stop the whole build.

A free identification layer, a licensed price column, and a precedence clause that makes redistribution a described path rather than an exception.

The simplest back calculation in Europe, a code that joins to nothing, and a reuse procedure with a 20 day deadline.

Published licence conditions, four intermediary obligations, and a conversion factor that has had no legal basis since 2012.

Free, monthly, complete inside its scope, and missing the field everyone expects.

No tax step, no margin inversion, a structured pack quantity field, and one download link that has to be resolved on every run.

The rare European source with an official ex-factory price per pack, and the evidence on what pharmaceutical reference data is worth.

A constant URL, a code that is a valid GTIN, and a margin schedule that has to be inverted numerically.

The authorities' own database had no paid prices as of 2022. What follows for market access, wholesale and hospital procurement.

Six verified rates, the Finnish change that the consolidated law text still missed, and the correct order of operations.

Four margin structures, thirteen countries compared, and the continuity test that proves how a scale must be read.

You can tell which German route applies when a medicine has no German marketing authorisation, and what evidence each route requires.

European pharma data splits into four provider types, each answering a different question. This guide maps them and matches your need to the right starting point.

German pharma data is a stack of sources, each authoritative for one layer. This guide groups them by job and shows how to reach each with English access.

A practitioner's guide to sourcing European and German pharma data for a pipeline: the join identifier, typed and dated prices, honest scope, and API versus bulk.

How Europe's fragmented shortage registers actually work, and how a structured, PZN-anchored data layer maps a shortage to an authorised alternative.

A practical sourcing guide to German drug price data: what it contains, where it comes from, how it is licensed, and what to check before you buy.

Understand why European drug price comparison is structurally hard, how external reference pricing links national prices, and what a usable cross-border dataset must contain.

Choosing a pharmaceutical data provider for the German market comes down to quality, currency, coverage, integration and no lock-in. pharmazie.com meets these by bundling 25+ databases in one search.

Monitoring a drug shortage is only half the job, the other half is finding an available alternative fast. pharmazie.com bundles shortage monitoring and the substitute search in one search.

Official drug data in Germany and the EU is spread across separate authority portals. pharmazie.com brings the publicly available data of these authorities together with specialist databases in one search.

A drug database with an interaction check screens every active-ingredient combination against a reviewed interaction dataset and flags critical interactions at once. pharmazie.com bundles this check with 25+ databases in one search.

The PZN identifies a German pharmaceutical product, but a bare number is not research. A professional PZN research system resolves the PZN into price, Fachinfo, supply status and identifiers in one search.

One English-accessible entry point to German, Austrian and Swiss drug information: Rote Liste, Austria Codex and the Swiss Compendium in one platform.

How aut-idem, section 130a rebate contracts, the substitution-exclusion list and the reference-price transparency list interact, and where the data lives.

A comparison of market-access and reimbursement pricing tools for DACH, scored on AMNOG depth, the AVWG transparency list, reimbursement history and English access.

A comparison of pharmaceutical data APIs for developers, including the German and DACH gap that the big US APIs do not cover.

The German pharmaceutical article master (Artikelstamm) explained, and how it differs from an ERP material master.

Why a single drug directory is no longer enough for clinical professionals, and how a consolidated platform with interaction checking compares.

How to check where an active ingredient is registered per EU country and map a German PZN to the equivalent marketing authorisation for parallel and single import.

How an API-first drug database with a live MSV3 client interface adds to a closed pharmacy system instead of replacing it.

For developers and data teams: whether to buy a German drug-data raw licence and run your own pipeline, or consume a maintained API.

A comparison of pharmaceutical price monitoring tools for the DACH market, scored on German depth: historical prices, AMNOG, alert granularity and English access.

A comparison of drug shortage tools for German and EU professional buyers, scored on what official lists lack: currency, alternatives, EU import and alerts.

A neutral comparison of German drug databases by system class, so professionals can choose the right data for their role.

Real-time availability and digital ordering from Sage 100 through the live MSV3 client interface.

You understand why section 130e SGB V shifts volumes rather than list prices, and how wholesalers should align assortment, tender monitoring and stock planning to it.

You get the full overview of the adopted BStabG: a fixed 15.5% manufacturer discount, a tightened price-volume rule, a higher vaccine discount and a planned location clause, with recommended actions per market role.

You learn how three simultaneous drivers move prices on the 1 July 2026 effective date: the higher pharmacy fee, the +2.2% inflation adjustment and the market-driven downward pressure.

You get an ordered overview of how industry, health insurance funds, the Bundesrat and the G-BA react to the three BStabG instruments and where the political fault lines in the legislative process lie.

You understand how the three BStabG instruments, the dynamic manufacturer discount, section 130e rebate contracts and the tightened price moratorium, reshape the patented-drug market and which players they concretely affect.

You learn why continuous price monitoring in the drug market is indispensable and how price trajectories, PZN price histories, reference prices and reimbursement amounts can be traced transparently.

Reimbursement status, fixed amounts and rebate data per PZN, in one search.

Originator, generic and reimbursement data per PZN and molecule, in one search.

Controlled-drug status, prices and availability for every PZN in one search.

A professional, source-backed map of Germany's medical cannabis market: how it is regulated, how imports and supply are governed, and how the products appear in German drug data.

What MSV3 is, who maintains it, how it replaced MSV2, the services and response codes it defines, and how a pharmacy connects to each wholesaler.

How German rebate contracts under section 130a SGB V decide which product a pharmacy must dispense, and how tenders, open house, aut idem and the statutory rebates fit together.

A verified, professional-grade briefing on exactly what Germany's 2026 pharma pricing reform changes, when each instrument takes effect, and what it means for manufacturers, wholesale and pharmacies.

What automatic biosimilar substitution changed in Germany: Section 40b for parenteral preparations since March 2024, Section 40c for finished biologics since April 2026, and the measurable effect on biologic prices.

A balanced, current answer to whether Germany should be your first European launch market, including the reasons it should not be.

A precise, date-verified guide to what the EU-US MRA covers, what it does not, and exactly when the batch testing waiver applies.

A precise map of the three unavailability states in German and EU pharmaceutical data, and how to read discontinuations as business development signals.

The full German shortage reporting chain, from the company notification to what a pharmacy is finally permitted to dispense.

A data-level guide to the German shortage register: what every field means, what the register omits, and how to find a supply-able alternative.

A precise map of the EU public drug databases, what each one is authoritative for, and exactly where each stops being reliable.

A defensible, auditable method for mapping a US medicinal product to its German counterpart, and the traps that break brand-based lookups.

A precise, professional map of German OTC and Rx classification, the law behind it, and the data fields that carry it.

You will be able to tell ABDA, Avoxa and ABDATA apart, and know which one actually produces the data you license.

A practical framework for choosing and integrating a drug data API, from identifier joins to licence thresholds.

How German wholesale pricing, supply obligations, MSV3 ordering and shortage sourcing work from the wholesaler's perspective.

The full pipeline from a manufacturer's IFA report to the price on a pharmacy screen, including deadlines, propagation times and the failure modes that corrupt the data.

A working map of every EU authorisation register, what each one answers, and how to combine them without producing silently wrong results.

A single worked example carried from manufacturer price to net payer cost, plus the seven checks that stop a drug price estimate from being wrong.

The full German medicine price calculation, worked end to end with numbers, from manufacturer selling price to pharmacy retail price.

A precise guide to what the German article master file contains, how its twice-monthly cycle works, and how ALBVVG, the combination discount and inflation adjustment changed its pricing fields.

The complete German launch sequence, from authorisation pathway to negotiated reimbursement price, with timelines and the new EU Joint Clinical Assessment layer.

A precise, source-verified map of which import pathway applies, who may use it, and what documentation each one demands.

A complete, current map of every mechanism that sets a German drug price, which body controls it, and which number matters commercially.

A practical operating model for maintaining SmPCs across many markets, including variations, CCDS and RSI control, referrals, and the ePI roadmap.

A clear, neutral explainer of who produces the ABDA database, what its modules contain, who licenses it, and how it differs from the ABDA-Artikelstamm.

You learn exactly what a G-BA resolution contains, what each added benefit category means commercially, and how to structure AMNOG outcomes so they can be benchmarked.

A practitioner's guide to the seven things about German drug price data that break systems built outside Germany, and how to model around them.

A role-by-role map of what pharmaceutical manufacturers, importers, wholesalers and pharmacies must have in place before the EU packaging regulation applies on 12 August 2026.

Why one question needs five databases, and how the clinical, commercial and logistics layers actually fit together in Germany and the EU.

The official EU reference text for a medicine, explained: legal basis, all 10 sections, and its role in pharmacovigilance.

You understand how German drug prices are formed, which regulatory frameworks shape them, and where to source the data in English.